Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ScreenPro (SCRN) has received two new four-month service agreements from television productions
  • ScreenPro provides turnkey coronavirus screening solutions to the private sector including testing, track and tracing with GoStop alerting software
  • This platform allows ScreenPro to be a nationwide provider of full-service testing solutions across Canada
  • ScreenPro Security Inc. (SCRN) is up 5.88 per cent and is trading at C$0.090 at 12:57 pm ET

ScreenPro Security Inc. (SCRN) has received two new four-month service agreements from television productions for rapid testing.

ScreenPro will provide its newly introduced rapid tests and proprietary GoStop mobile alerting software.

CEO John McMullen remarked,

“To continue servicing our current clients and onboard new productions with this new test technology and COVID passport, GoStop, is a testament to the services ScreenPro provides. Through PCR and Rapid testing, we help businesses move forward.”

ScreenPro provides turnkey coronavirus screening solutions to the private sector including testing, track and tracing with GoStop alerting software.

ScreenPro’s unique access to multiple manufacturers of high-quality South Korean test kits and its strategic partnership with Canvas Labs in Vancouver and Integrated Explorations in Ontario.

This platform allows ScreenPro to be a nationwide provider of full-service testing solutions across Canada.

ScreenPro Security Inc. (SCRN) is up 5.88 per cent and is trading at C$0.090 at 12:57 pm ET.

More From The Market Herald
Levitee Labs - CEO, Pouya Farmand.

" Levitee Labs (CSE:LVT) partners with Adracare for addiction and mental health support

Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services.

" Cardiol Therapeutics (TSX:CRDL) expands phase II/III trial of CardiolRx

Cardiol Therapeutics (CRDL) is expanding its LANCER trial to include several hospital centers in Brazil, Mexico, and Canada.

" XORTX Therapeutics (CSE:XRX) closes public offering

XORTX Therapeutics (XRX) announced the closing of a US$12M public offering.

" Marvel Biosciences (TSXV:MRVL) updates the status of its MB-204 manufacturing efforts

Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.